Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health
Absci (NASDAQ: ABSI) and Invetx announced a strategic partnership to develop an innovative Half-Life Extension (HLE) platform for animal health applications. The collaboration will utilize Absci's generative AI Drug Creation models to design novel modular antibody sequences for specific animal species.
Under the agreement, Invetx will have rights to use the HLE platform in multiple products to enhance therapeutic effect duration and customer convenience. The partnership includes R&D funding, election fees, milestone payments, and royalties on a per-product basis. Initial applications will focus on large-market indications in canines, with potential expansion to other companion animals.
Absci (NASDAQ: ABSI) e Invetx hanno annunciato una partnership strategica per sviluppare una piattaforma innovativa di Estensione della Vita Semilunga (HLE) per applicazioni nella salute degli animali. La collaborazione sfrutterà i modelli di Creazione di Farmaci basati su AI generativa di Absci per progettare nuove sequenze di anticorpi modulari specifiche per diverse specie animali.
In base all'accordo, Invetx avrà i diritti di utilizzare la piattaforma HLE in diversi prodotti per migliorare la durata dell'effetto terapeutico e la comodità per i clienti. La partnership include finanziamenti per R&S, commissioni per elezioni, pagamenti per traguardi e diritti d'autore su base per prodotto. Le applicazioni iniziali si concentreranno su indicazioni di ampio mercato nei cani, con potenziale espansione ad altri animali da compagnia.
Absci (NASDAQ: ABSI) e Invetx anunciaron una asociación estratégica para desarrollar una plataforma innovadora de Extensión de Vida Media (HLE) para aplicaciones en salud animal. La colaboración utilizará los modelos de Creación de Medicamentos de IA generativa de Absci para diseñar nuevas secuencias de anticuerpos modulares para especies animales específicas.
Según el acuerdo, Invetx tendrá derechos para usar la plataforma HLE en múltiples productos para mejorar la duración del efecto terapéutico y la comodidad del cliente. La asociación incluye financiación para I+D, tarifas de elección, pagos por hitos y regalías por producto. Las aplicaciones iniciales se centrarán en indicaciones de gran mercado en perros, con la posible expansión a otros animales de compañía.
Absci (NASDAQ: ABSI)와 Invetx가 동물 건강 응용을 위한 혁신적인 반감기 연장(HLE) 플랫폼을 개발하기 위한 전략적 파트너십을 발표했습니다. 이번 협력에서는 Absci의 생성 AI 약물 생성 모델을 활용하여 특정 동물 종에 적합한 새로운 모듈형 항체 서열을 설계합니다.
합의에 따라 Invetx는 치료 효과 지속 시간과 고객 편의성을 강화하기 위해 여러 제품에 HLE 플랫폼을 사용할 권리를 가지게 됩니다. 이 파트너십은 연구 개발 자금, 선거 수수료, 이정표 지급 및 로열티를 제품별로 포함합니다. 초기 응용 프로그램은 개를 대상으로 한 대규모 시장 지표에 초점을 맞출 것이며, 향후 다른 반려 동물로의 확장이 가능합니다.
Absci (NASDAQ: ABSI) et Invetx ont annoncé un partenariat stratégique pour développer une plateforme innovante d'Extension de Durée de Vie (HLE) pour des applications en santé animale. Cette collaboration utilisera les modèles de création de médicaments basés sur l'IA générative d'Absci pour concevoir de nouvelles séquences d'anticorps modulaires adaptées à des espèces animales spécifiques.
En vertu de l'accord, Invetx aura le droit d'utiliser la plateforme HLE dans plusieurs produits afin d'améliorer la durée de l'effet thérapeutique et la commodité pour les clients. Ce partenariat comprend financement en R&D, frais de sélection, paiements d'étape et redevances sur une base par produit. Les applications initiales se concentreront sur des indications à fort potentiel sur le marché pour les chiens, avec une éventuelle expansion vers d'autres animaux de compagnie.
Absci (NASDAQ: ABSI) und Invetx haben eine strategische Partnerschaft angekündigt, um eine innovative Halbwertserweiterungsplattform (HLE) für den Bereich Tiergesundheit zu entwickeln. Die Zusammenarbeit wird die generativen KI-Modelle von Absci zur Entwicklung neuartiger modularer Antikörpersequenzen für spezifische Tierarten nutzen.
Im Rahmen der Vereinbarung erhält Invetx das Recht, die HLE-Plattform in mehreren Produkten zu nutzen, um die Dauer der therapeutischen Wirkung und den Kundenkomfort zu verbessern. Die Partnerschaft umfasst Forschungs- und Entwicklungsmittel, Wahlgebühren, Meilensteinzahlungen und Lizenzgebühren pro Produkt. Die ersten Anwendungen konzentrieren sich auf große Marktindikationen bei Hunden, mit möglicher Expansion auf andere Haustiere.
- Partnership includes multiple revenue streams: R&D funding, election fees, milestone payments, and royalties
- Expansion into animal health market represents new revenue opportunity
- Initial focus on large-market canine indications with potential for expansion
- None.
Insights
The strategic partnership between Absci and Invetx represents a calculated expansion into the lucrative animal health market, estimated at
The deal structure includes multiple revenue streams - R&D funding, election fees, milestone payments and product royalties - providing Absci with both near-term cash flow and long-term value potential. For context, animal health drug royalties typically range from
The most compelling aspect is Absci's leveraging of its existing AI platform to enter a new market vertical without significant additional R&D investment. This capital-efficient approach to market expansion could accelerate revenue growth while maintaining operational efficiency.
The application of Absci's generative AI platform to animal therapeutics showcases an intelligent technology transfer strategy. The key technical advantage lies in the platform's ability to adapt human antibody design principles to species-specific requirements, demonstrating the versatility of their AI models.
The modular nature of the planned HLE platform is particularly significant as it suggests potential for rapid scalability across different therapeutic products and animal species. This architectural approach could create substantial barriers to entry for competitors while enabling efficient product development cycles.
In simpler terms: imagine having a smart LEGO set that can build custom blocks for different animals' needs - that's essentially what Absci's AI platform will do for veterinary medicine, making drugs last longer in animals' bodies while reducing the frequency of needed doses.
Collaboration leverages Absci’s leading generative AI Drug Creation models to design a novel antibody Half-Life Extension (HLE) platform for animal health applications
VANCOUVER, Wash. and BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Invetx, a pioneer in protein-based therapeutics for animal health, today announced a strategic partnership to harness Absci’s AI Drug Creation models to create an innovative Half-Life Extension (HLE) platform for animal health applications.
“Absci has built a leading generative AI Drug Creation platform for therapeutic antibodies and we’re excited to bring this expertise into animal health,” said Sean McClain, Founder and CEO of Absci. “We look forward to working with Invetx to address the large underserved animal health market by leveraging our proven success in designing Half-Life Extension technologies for human antibodies to advance the standard of care in veterinary medicine.”
Under the terms of the agreement, Absci will utilize its AI models to design novel modular antibody sequences that confer Half-Life Extension in specific animal species, Invetx will have rights, subject to the agreement’s financial and other terms, to use the HLE platform in multiple products to enhance duration of therapeutic effect and customer convenience, both significant potential differentiators in the animal health market. The partnership includes R&D funding, as well as election fees, milestone payments, and royalties on a per-product basis.
“Invetx is a pioneer in creating novel, protein-based animal health therapeutics and we are excited to leverage the power of AI to enhance the development of our pipeline", said Juergen Horn, President of Invetx. “We selected Absci for this collaboration because of their leading platform for generative AI design of human antibodies. By partnering together, we have an opportunity to build a scalable platform for bringing innovative specialty therapeutics for companion animals to market.”
The collaboration has the potential to address significant unmet needs in animal health, with initial applications for large-market indications in canines, and with the potential to expand to other companion animals.
About Absci
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.
About Invetx
Invetx is a pioneer in creating novel, protein-based animal health therapeutics to transform standards of care in veterinary medicine. The company leverages a best-in-class, fully integrated biotechnology platform for the discovery, development, and manufacturing of veterinary monoclonal antibodies, and is developing a diverse product pipeline addressing chronic and severe diseases in companion animals. Invetx was acquired by Dechra Pharmaceuticals Limited, a global specialist veterinary pharmaceuticals business, in July 2024. Invetx is headquartered in Boston, Massachusetts. For more information, see www.invetx.com.
Absci Forward-Looking Statements
Certain statements in this press release that are not historical facts are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements containing the words “will,” “may,” “pursues,” “anticipates,” “plans,” “believes,” “aims,” “potential,” “forecast,” “estimates,” “extends,” “expects,” and “intends,” or similar expressions. We intend these forward-looking statements, including statements regarding the capabilities of our Integrated Drug Creation platform, our technology development efforts and the application of those efforts, the potential benefits of our partnership with Invetx, the plans and success of our current and future partnerships and the ability to generate advancements towards treating disease using generative AI drug creation to accelerate the development of novel candidate therapies, the anticipated value to us under our partnerships, and our internal therapeutic asset programs, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and we make this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved, and furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks and uncertainties relating to our ability to effectively collaborate on research, drug discovery and development activities with our partners or potential partners, our dependence on third parties to support our internal development programs, including for the manufacture and supply of preclinical and clinical supplies of our product candidates or components thereof, our existing and potential partners’ ability and willingness to pursue the development and commercialization of programs or product candidates under the terms of our partnership agreements, and overall market conditions and regulatory developments that may affect our and our partners’ activities under these agreements, along with those risks set forth in our most recent periodic report filed with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.
Absci Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com
Absci Media Contact
press@absci.com
Invetx Media Contact
Jonny Armstrong
Global Corporate Communications Director
jonny.Armstrong@dechra.com
FAQ
What is the financial structure of Absci (ABSI) and Invetx's partnership agreement?
What is the main focus of ABSI's collaboration with Invetx announced in January 2025?
How will ABSI's AI technology be used in the Invetx partnership?
What markets will the ABSI-Invetx partnership target initially?
